Compare Stocks: ABUS, TNGX, AMLX, and LEGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$5.15 +0.6%	$4.75	$3.50 ▼ $5.45	$1.02B	0.62	2.34 million shs	5.20 million shs
AMLX Amylyx Pharmaceuticals	$34.10 +0.4%	$23.91	$9.75 ▼ $41.14	$3.80B	-0.13	1.69 million shs	885,478 shs
LEGN Legend Biotech	$21.52 -1.1%	$22.86	$16.24 ▼ $37.50	$4.17B	0.4	2.44 million shs	811,970 shs
TNGX Tango Therapeutics	$22.52 -1.1%	$27.23	$6.25 ▼ $34.39	$3.80B	1.12	3.39 million shs	1.46 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+0.39%	-0.97%	+15.84%	+20.47%	+30.28%
AMLX Amylyx Pharmaceuticals	-1.54%	-8.66%	+55.69%	+154.95%	+245.12%
LEGN Legend Biotech	-0.64%	+6.10%	+13.70%	-33.32%	-39.50%
TNGX Tango Therapeutics	+1.97%	-9.97%	-22.48%	+12.56%	+239.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$5.15 +0.6%	$4.75	$3.50 ▼ $5.45	$1.02B	0.62	2.34 million shs	5.20 million shs
AMLX Amylyx Pharmaceuticals	$34.10 +0.4%	$23.91	$9.75 ▼ $41.14	$3.80B	-0.13	1.69 million shs	885,478 shs
LEGN Legend Biotech	$21.52 -1.1%	$22.86	$16.24 ▼ $37.50	$4.17B	0.4	2.44 million shs	811,970 shs
TNGX Tango Therapeutics	$22.52 -1.1%	$27.23	$6.25 ▼ $34.39	$3.80B	1.12	3.39 million shs	1.46 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+0.39%	-0.97%	+15.84%	+20.47%	+30.28%
AMLX Amylyx Pharmaceuticals	-1.54%	-8.66%	+55.69%	+154.95%	+245.12%
LEGN Legend Biotech	-0.64%	+6.10%	+13.70%	-33.32%	-39.50%
TNGX Tango Therapeutics	+1.97%	-9.97%	-22.48%	+12.56%	+239.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	-2.91% Downside
AMLX Amylyx Pharmaceuticals	3.00	Buy	$36.50	7.04% Upside
LEGN Legend Biotech	2.47	Hold	$53.43	148.27% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	92.99% Upside

Current Analyst Ratings Breakdown

Latest ABUS, TNGX, AMLX, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
9/4/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/1/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $57.00
8/26/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/19/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $55.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$28.00 ➝ $52.00
8/18/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $42.00
8/18/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $55.00
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$66.00 ➝ $68.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$14.08M	72.46	N/A	N/A	$1.31 per share	3.93
AMLX Amylyx Pharmaceuticals	$87.37M	43.49	N/A	N/A	$2.15 per share	15.86
LEGN Legend Biotech	$1.03B	4.05	N/A	N/A	$6.35 per share	3.39
TNGX Tango Therapeutics	$62.38M	60.87	N/A	N/A	$6.08 per share	3.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	6.52	N/A	N/A	84.22%	90.98%	82.34%	11/16/2026 (Estimated)
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	18.39	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)

Latest ABUS, TNGX, AMLX, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	81.42
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
LEGN Legend Biotech	N/A	3.04	2.94
TNGX Tango Therapeutics	N/A	50.82	50.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
AMLX Amylyx Pharmaceuticals	95.84%
LEGN Legend Biotech	70.89%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
AMLX Amylyx Pharmaceuticals	10.90%
LEGN Legend Biotech	0.02%
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	198.11 million	158.68 million	Optionable
AMLX Amylyx Pharmaceuticals	200	111.42 million	99.28 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
TNGX Tango Therapeutics	90	168.61 million	157.65 million	Optionable

ABUS, TNGX, AMLX, and LEGN Headlines

Recent News About These Companies

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3 at 4:05 PM | globenewswire.com

390,920 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Bank of New York Mellon Corp

September 2 at 3:28 AM | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Moderate Buy" by Brokerages

September 2 at 1:45 AM | americanbankingnews.com

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1 at 7:00 AM | globenewswire.com

181,212 Shares in Tango Therapeutics, Inc. $TNGX Purchased by The Manufacturers Life Insurance Company

September 1 at 4:47 AM | marketbeat.com

Alyeska Investment Group L.P. Increases Holdings in Tango Therapeutics, Inc. $TNGX

September 1 at 3:03 AM | marketbeat.com

Nantahala Capital Management LLC Takes Position in Tango Therapeutics, Inc. $TNGX

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Tango Therapeutics, Inc. $TNGX

August 28, 2026 | marketbeat.com

Oxford Nanopore Technologies (OTCMKTS:ONTTF) vs. Tango Therapeutics (NASDAQ:TNGX) Head to Head Contrast

August 28, 2026 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Raises Stock Position in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Jupiter Topco LLC Invests $157.99 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Boone Capital Management LLC Invests $14.24 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 4.8% - Here's Why